In:
Blood, American Society of Hematology, Vol. 104, No. 11 ( 2004-11-16), p. 3118-3118
Abstract:
This study was undertaken to determine the prognostic value of proliferation rate in Hodgkin and Reed-Sternberg (HRS) cells in pediatric and adolescent patients with Hodgkin’s disease (HD). 231 paraffin-embedded biopsies were immunostained with proliferation associated monoclonal antibodies Ki-S5 (Ki-67 antigen) and Ki-S2 (repp86 antigen), which is characterized by an expression pattern restricted to G2, S and M phases. Results were compared with clinical data from 224 patients included in multicenter GPOH HD-90 and HD-95 trials. High Ki-67 expression was a striking feature (median: 80%, range: 20–100%) in contrast to low Ki-S2 expression (median: 20%, range: 10–80%). Apoptosis was assessed in 133 patients by TUNEL method (median: 10%, range: & lt;10–70%). Proliferation rate was independent of histological subtype, stage, presence of B symptoms and allocation to treatment group. Probability of event-free and overall survival at 5 years was 91% and 98%, respectively with no significant differences in patients with low or high proliferation rate. The difference between Ki-67 and repp86 expression in HRS cells points to a possible cell cycle arrest in G1 phase, which may explain the obvious paradoxon of a highly proliferating but slowly growing paucicellular tumor. High proliferation rate does not seem to be an adverse prognostic factor in pediatric patients with HD treated by effective chemoradiotherapy regimens.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood.V104.11.3118.3118
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2004
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7
